HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Nails Supplement Marketers For “Bogus” Free Weight-Loss Samples

This article was originally published in The Tan Sheet

Executive Summary

Firms marketing products or services online must clearly and conspicuously disclose billing practices and obtain affirmative consent before charging consumers, or potentially face hefty fines for violating consumer protection laws, the Federal Trade Commission cautions

You may also be interested in...



Desert Labs Seeks To Overcome Hoodia Market’s Reputation

As Desert Labs contemplated a launch plan for hoodia supplements sourced from its own farm, enforcement actions were mounting against misleading advertising for hoodia products.

In Brief

Prestige Brands buys Dramamine

NextClick settles false-marketing charges

NextClick Media, Kenneth Chan and Albert Chen will pay $315,000 to resolve allegations they sold "bogus smoking cessation patches" and illegally debited consumers' bank accounts, the Federal Trade Commission announces Nov. 9. The defendants allegedly failed to tell consumers they would automatically charge them up to $99.95 monthly for products unless they cancelled if they accepted a "free" 10-day trial of various herbal products, including smoking cessation patches Nicocure, Stop Smoking 180 and Zero Nicotine (1"The Tan Sheet" May 12, 2008). The settlement is the latest in an FTC crackdown on negative-option marketing (2"The Tan Sheet" Feb. 16, 2009)

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS135746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel